OMDA Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 5.43%, SMA50 -9.31%, SMA200 -31.03%). The stock’s 14-day RSI is 50.02 (neutral), while the ATR of 0.91 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -54.4% below its high and over 25.97% above its low. Average 10-day trading volume of 1.20 million shares is in line with the 3-month average of 1.19 million, indicating normal recent market interest.

Omada Health has 57.57 million shares outstanding. The public float is 41.54 million shares, elevated short interest at 3.06% of float. This equals 1.58 million shares. The short ratio is 3.17 days. Institutional investors hold 76.7% of the float. Insiders own 12.91%. Duffy Sean P. holds 126.64 thousand shares, Shao Wei-Li has 69.08 thousand shares and Cook Steven L. has 57.57 thousand shares. Over the past six months, insider transactions show net selling. They sold 150.38 thousand shares across 5 transactions.

Our AI price prediction model suggests that Omada Health stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -24.63%, with price expected at $9.76 by March 11, 2026, within a range of $8.58 to $10.89 3-Month Outlook: Projected rise of 339.61%, reaching $56.93 by May 26, 2026, with a range of $56.68 to $57.20. 1-Year Outlook: Projected loss of -79.15%, with price at $2.70 by February 25, 2027, within a range of $2.50 to $2.94.

Omada Health (NASDAQ:OMDA) shares are flat -0.25% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Omada Health trading at a premium to the broader market with a P/E of -26.17. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $25.05, suggesting 93.44% upside. Our AI forecast model points to short-term weakness (-24.63% over two weeks), a medium-term rise (339.61% over three months), and a longer-term loss (-79.15% over one year), with expected trading ranges indicating moderate volatility.

Omada Health last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$12.16. This means the shares are trading below this model’s fair value.

Omada Health (NASDAQ:OMDA) closed at $12.95 USD, gaining $1.00 (8.37%) from the previous close of $11.95. The stock is currently mid-range between its 52-week high and low $10.28 and $28.40. With a market capitalization of about $749.91 million, Omada Health is classified as a small-cap and shows higher-than-market volatility (beta ~6.84). Key stats such as the average daily volume over the past year has been around 1.21 million shares, in line with its 52-week average. Headquartered in San Francisco, CA, Omada Health operates in the Healthcare sector and the Medical - Healthcare Information Services industry. Led by CEO Sean Duffy, the company employs approximately 849 people and listed since June 06, 2025. Omada Health is a U.S.-based virtual-care provider offering clinically validated programs for chronic conditions like cardiometabolic disease, musculoskeletal care, and behavioral health—delivered digitally between doctor visits.

Analyst sentiment is bullish. Analyst rating data shows there are 13 Strong Buy ratings, 7 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $29.00 to $17.00. The high target offers 123.94% upside. The low target suggests 31.27% downside. The mean target is $25.05. This offers 93.44% upside. Omada Health earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -40.0%. The prior quarter beat by -10.0%. Over the last six quarters, Apple has recorded several small beats. These include -10.0% in August 07, 2025.

Omada Health trades at a P/E ratio of -26.17, slightly below the S&P 500 average, with a price-to-sales ratio of 3.23 and a price-to-book ratio of 3.15 trading at moderately above to book value. The P/FCF stands at -144.55, also below market averages.